The invention discloses application of Demethylzeylasteral (T-96) in preparation of drugs for preventing or treating
hepatic fibrosis, and belongs to the technical field of biological medicines. In-vivo and in-vitro experiments prove that the Demethylzeylasteral (T-96) can inhibit activation of hepatic stellate cells, reduce collagen deposition in livers of
hepatic fibrosis mice, inhibit fibroplasia, improve
liver functions and down-regulate expression of
hepatic fibrosis related proteins, which indicates that the Demethylzeylasteral (T-96) has an anti-hepatic
fibrosis effect. In addition,
transcriptome sequencing and experimental results show that the Demethylzeylasteral (T-96) can inhibit activation of the hepatic stellate cells by regulating expression of proteins such as AGAP2 and the like so as to improve hepatic
fibrosis, and the Demethylzeylasteral (T-96) has the advantages of small toxic and side effects, wide
raw material sources, low production cost and the like. Therefore, the Demethylzeylasteral (T-96) can be used for preparing drugs and pharmaceutical compositions for preventing / treating hepatic
fibrosis, and has good development and application values.